Neuropsychopharmacology Reports
August 27, 2026
Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C. Strickland et al.
INTRODUCTION: Interest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent...
The International Journal of Neuropsychopharmacology
May 5, 2026
Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar et al.
BACKGROUND: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. METHODS: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence,...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
May 15, 2025
Chitra Vinnakota, Matthew R Hudson, Kazutaka Ikeda et al.
6 citations
Working memory relies on synchronised network oscillations involving complex interplay between pyramidal cells and GABAergic interneurons. NMDA receptor (NMDAR) antagonists influence both network oscillations and working memory, but the relationship between these two consequences has not been elucidated. This study aimed to determine the effect of NMDAR antagonists on network oscillations...
Journal of Pharmacological Sciences
March 1, 2024
Aimi Yamagishi, Yuiko Ikekubo, Masayoshi Mishina et al.
6 citations
Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has attracted attention for its acute and sustained antidepressant effects in patients with depression. Hydroxynorketamine (HNK), a metabolite of ketamine, exerts antidepressant effects without exerting ketamine's side effects and has attracted much attention in recent years. However, the detailed pharmacological mechanism of action...
Journal of Neuroscience Research
2024
Chitra Vinnakota, Anna Schroeder, Xin Du et al.
7 citations
Noncompetitive NMDA receptor (NMDAR) antagonists like phencyclidine (PCP) and ketamine cause psychosis-like symptoms in healthy humans, exacerbate schizophrenia symptoms in people with the disorder, and disrupt a range of schizophrenia-relevant behaviors in rodents, including hyperlocomotion. This is negated in mice lacking the GluN2D subunit of the NMDAR, suggesting the GluN2D subunit mediates...
Neuropsychopharmacology Reports
February 6, 2021
Yoko Hagino, F. Scott Hall, George R. Uhl et al.
3 citations
Abstract Aims 5‐Methoxy‐ N , N ‐diisopropyltryptamine (5‐MeO‐DIPT) is a synthetic orally active hallucinogenic tryptamine analogue. The present study examined whether the effects of 5‐MeO‐DIPT involve the serotonin transporter (SERT) and serotonin 5‐hydroxytryptamine‐1A (5‐HT 1A ) receptor in the striatum and prefrontal cortex (PFC). Methods We investigated the effects of 5‐MeO‐DIPT on...
Current Neuropharmacology
March 1, 2011
Yoko Hagino, Yukio Takamatsu, Hideko Yamamoto et al.
64 citations
3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DA(ex)) and serotonin (5-HT(ex)) levels in the striatum and prefrontal cortex (PFC) using in vivo...